News / Taiwan / cnyes
Adimmune August Revenue Grows 34% YoY
Health Technology · Biotechnology · cnyes · 2026-09-04
4142
Adimmune (4142) reported August revenue of NT$97.92 million, a 34.46% year-over-year increase, showing resilience compared to the biotech sector index.
What Happened
Revenue Overview: Adimmune (4142) reported August 2026 revenue of NT$97.92 million, reflecting a 34.46% year-over-year increase, though it experienced a 68.23% month-over-month decline.
Cumulative Results: The company's cumulative revenue for the first eight months of 2026 reached NT$555 million, representing a year-to-date growth of 12.56%.
Stock Performance: Trading at NT$17.55, the stock declined 1.68% over the past five days, which is significantly better than the 9.59% drop seen in the biotech sector index.
Business Operations: Adimmune specializes in the manufacturing and development of vaccines, serums, diagnostic reagents, and biological products, alongside import and export services.